Nearly half of all patients presenting with heart failure have normal or near normal left ventricular systolic function. Optimal treatment strategies for this large patient group remain unclear. Small mechanistic studies have suggested diastolic function may be improved by mineralocorticoid-receptor antagonists. Whether this mechanistic benefit translates into better patient outcomes is not known. In the […]
Tag: spironolactone
Aldo-DHF: spironolactone improves diastolic function
Heart failure with preserved ejection fraction (HF-PEF) accounts for more than 50% of heart failure cases. To date, medical therapy has failed to show improvements in diastolic dysfunction, cardiac remodelling, or cardiovascular outcomes. As mineralocorticoid receptor activation by aldosterone contributes to the pathophysiology of HF through several different mechanisms, the Aldosterone Receptor Blockade in Diastolic […]